Primary Outcome Measures
- Incidence of DLTs (dose-limiting toxicity) [ Time Frame: 6 weeks (42 days) ]
Eligibility
- Inclusion Criteria
- Signed informed consent
- Male or female subjects ≥ 18 years of age
- ECOG PS (Eastern Cooperative Oncology Group Performance Status) of 0 or 1
- Subjects with advanced, histologically or cytologically confirmed epithelioid mesothelioma (pleural or peritoneal) or serous ovarian cancer, not responsive to standard therapy or lacking appropriate treatment options
- Availability of fresh or archival tumor samples
- Adequate bone marrow, liver, and renal function, as assessed by the following laboratory requirements (within 28 days before start of study drug treatment)
- Negative serum pregnancy test
- Exclusion Criteria
- Impaired cardiac function or clinically significant cardiac disease
- Any clinically significant pericardial effusion
- Subjects known to be affected by genetic defects linked to radiation hypersensitivity
- Infections of CTCAE (Common Terminology Criteria for Adverse Events) version 4.03 Grade 2 not responding to therapy or active clinically serious infections of CTCAE Grade >2 will be excluded
- History of anaphylactic reactions to monoclonal antibody therapy
- Myelodysplastic syndrome (MDS)/treatment-related acute myeloid leukemia (t-AML) or with features suggestive of MDS/AML
